Purple Biotech Ltd. (PPBT) Appoints Ori Hershkovitz to its Board

Purple Biotech Ltd. (NASDAQ: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Ori Hershkovitz, a long-time life sciences industry investor, to its Board of Directors.

“We are thrilled to welcome Ori to the Purple Biotech Board of Directors,” said Dr. Eric Rowinsky, Chairman of the Board of Purple Biotech. “Ori has spent many years investing in and advising development-stage life sciences companies. We look forward to leveraging his industry and financial expertise as we continue to execute on our corporate growth initiatives.”

“Purple Biotech has a compelling oncology-focused pipeline, highlighted by CM24 and NT219, with a great potential to transform the therapeutic options of many cancer patients,” said Mr. Hershkovitz. “I look forward to working with the other members of the Board and the Company's experienced management team to support Purple Biotech’s continued development and to drive long-term shareholder value.”

You May Also Be Interested In

• Virtus Investment Partners names Jack Boyce to its board
• Victoria's Secret adds former Starbucks tech chief to its board
• Newmont names ex-BHP finance chief Peter Beaven to its board